Study of Occupational Risk Factors for Biliary and Pancreatic Cancers

Sponsor
Centre Hospitalier Intercommunal Creteil
Study ID
NCT07668024
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

PANTOXBIL is a research project developed in the context of the increasing incidence of biliary tract and pancreatic cancers in France. Despite recent therapeutic advances, the prognosis of these cancers remains poor. Known risk factors do not fully explain the increase in incidence observed over recent decades. This suggests the possible role of emerging occupational and environmental risk factors, as reported in several epidemiological studies. The PANTOXBIL study is based on the analysis of detailed curriculum laboris data (employment periods, occupations, tasks performed, and occupational exposures) collected during two multicenter phase II clinical trials, TEDOPAM and IMMUNOBIL, conducted between 2018 and 2021 in patients with pancreatic and biliary tract cancers. An occupational exposure assessment was performed to calculate semi-quantitative cumulative exposure indices for each exposure or group of exposures for every participant. These indices will be compared with those of healthy controls from the CHOPPI cohort, initially designed to study occupational risk factors in COPD. PANTOXBIL is a matched case-control study based on sex, age, and smoking status. The aim is to compare cumulative occupational exposure indices between cases and controls in order to generate new hypotheses regarding occupational risk factors for biliary tract and pancreatic cancers.

Key Dates

First listed
Jun 25, 2026
Start date
Aug 31, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
210 participants (estimated)

Arms

  • Arm: Patients with biliary tract or pancreatic cancers
    Patients included in the TEDOPAM or IMMUNOBIL trials diagnosis of biliary tract or pancreatic cancer
  • Arm: Control patients
    Subjects from the CHOPPI cohort without biliary tract or pancreatic cancer

Primary Outcome Measure

Compare the occupational exposure index to targeted toxicants [ Time Frame: Day 1 ]

Central Contacts

Find similar trials

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials

Related Studies